GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy
Acta Biochimica et Biophysica Sinica · 2025
DOI: 10.3724/abbs.2025013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, 2025. Verfasst von Hanxue Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya…. Hauptthemen laut MEDLINE: Genome-Wide Association Study, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Platinum-based chemotherapy remains the mainstay for non-small cell lung cancer (NSCLC), but it frequently causes dose-limiting myelosuppression, with significant individual variability in susceptibility. However, the genetic basis of myelosuppression side effects remains elusive, greatly hindering personalized therapeutic approaches. In this study, we perform a comprehensive genome-wide association analysis on 491 NSCLC patients receiving platinum-based chemotherapy, examining 4,690,998 single-nucleotide polymorphisms (SNPs) to identify relevant genetic variants. LDBlockShow, FUMA, and MAGMA are utilized to explore linkage disequilibrium, expression quantitative trait loci (eQTLs), chromatin interaction, and conduct gene-based and gene set-based analysis of candidate SNPs. The GWAS results reveal that rs6856089 and its linked SNPs are significantly associated with platinum-based chemotherapy-induced myelosuppression. Specifically, patients with the A allele of rs6856089 have a significantly lower risk of myelosuppression (odds ratio (OR) = 0.1300, P = 7.59 × 10–8). Furthermore, gene-based analysis reveals that EMCN (P = 2.47 × 10–5), which encodes endomucin, a marker for hematopoietic stem cells, might mediate myelosuppression. This study provides a scientific basis for the individual differences in platinum-based chemotherapy-induced myelosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.
- Institute of Clinical Pharmacology, Engineering Research Center for Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha 410078, China.
- Departments of Orthopaedics, Xiangya Hospital, Central South University, Changsha 410008, China.
- Departments of Gerontology, Xiangya Hospital, Central South University, Changsha 410008, China.
- Departments of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
Zitieren
APA
Huang, H., Liu, J., Xiao, Q., Mao, C., She, L., Yu, L., Yu, B., Lei, M., Gao, Y., He, B., Pan, P., Li, X., Yin, J., & Liu, Z. (2025). GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025013
Vancouver
Huang H, Liu J, Xiao Q, Mao C, She L, Yu L, et al. GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy. Acta Biochimica et Biophysica Sinica. 2025. doi:10.3724/abbs.2025013
BibTeX
@article{Huang2025,
author = {Huang, Hanxue and Liu, Junyan and Xiao, Qi and Mao, Chenxue and She, Lei and Yu, Lulu and Yu, Bing and Lei, Mengrong and Gao, Ying and He, Baimei and Pan, Pinhua and Li, Xi and Yin, Jiye and Liu, Zhaoqian},
title = {GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy},
journal = {Acta Biochimica et Biophysica Sinica},
year = {2025},
doi = {10.3724/abbs.2025013}
}
EUVIMED